Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients
Table 2
Propensity-adjusted and multivariable adjusted regression analyses for survival endpoints.
Propensity-adjusted Cox regression
PFS
MFS
OS
Hazard ratio
95% CI
value
Hazard ratio
95% CI
value
Hazard ratio
95% CI
value
Testosterone cohort
100–239
0.71
0.28 to 1.80
0.47
1.31
0.34 to 5.03
0.70
0.99
0.35 to 2.83
0.98
240–593
Reference
Reference
Reference
594+
0.78
0.35 to 1.74
0.55
0.62
0.14 to 2.72
0.53
0.75
0.26 to 2.11
0.58
NCI comorbidity score
3.06
0.44 to 21.23
0.26
Coronary artery disease
No
Reference
Yes
0.86
0.19 to 3.84
0.84
Multivariable Cox regression
PFS
MFS
OS
Hazard ratio
95% CI
value
Hazard ratio
95% CI
value
Hazard ratio
95% CI
value
Testosterone cohort
100–239
0.74
0.29 to 1.88
0.53
1.34
0.32 to 5.60
0.69
0.86
0.27 to 2.74
0.81
240–593
Reference
Reference
Reference
594+
0.48
0.19 to 1.19
0.11
0.41
0.08 to 2.22
0.30
0.53
0.13 to 2.19
0.38
Age (yrs)
1.0
0.96 to 1.06
0.85
1.02
0.95 to 1.10
0.57
1.06
0.99 to 1.13
0.08
ISUP grade group
Group 1,2
Reference
Reference
Reference
Group 3
1.4
0.54 to 3.59
0.49
1.62
0.28 to 9.44
0.59
1.06
0.29 to 3.83
0.93
Group 4,5
1.7
0.65 to 4.44
0.28
4.85
1.06 to 22.24
0.04
1.77
0.43 to 7.40
0.43
Log (psa)
1.5
0.91 to 2.48
0.11
1.47
0.65 to 3.33
0.35
1.31
0.64 to 2.68
0.46
Clinical T-stage
T1c
Reference
Reference
Reference
T2
0.72
0.36 to 1.44
0.36
0.35
0.09 to 1.30
0.12
1.03
0.42 to 2.51
0.95
T3a/b
4.85
1.20 to 19.60
0.03
1.39
0.25 to 7.72
0.71
7.28
0.94 to 56.64
0.06
NCI comorbidity score
2.65
0.43 to 16.27
0.29
Coronary artery disease
No
Reference
Yes
0.91
0.17 to 4.78
0.92
Clinical T-stage derived from the American Joint Committee on Cancer (AJCC) 8th edition. PFS = progression-free survival, MFS = metastasis-free survival, OS = overall survival, ISUP = International Society of Urological Pathologists, NCI = National Cancer Institute.
